3D echocardiographic global longitudinal strain can identify patients with mildly-to-moderately reduced ejection fraction at higher cardiovascular risk.


Journal

The international journal of cardiovascular imaging
ISSN: 1875-8312
Titre abrégé: Int J Cardiovasc Imaging
Pays: United States
ID NLM: 100969716

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 11 01 2019
accepted: 25 03 2019
pubmed: 3 4 2019
medline: 3 9 2019
entrez: 3 4 2019
Statut: ppublish

Résumé

Severely reduced left ventricular (LV) ejection fraction (EF) derived from 2D echocardiographic (2DE) images is associated with increased mortality and used to guide therapeutic choices. Global longitudinal strain (GLS) is more sensitive than LVEF to detect abnormal LV function, and accordingly may help identify patients with mildly-to-moderately reduced LVEF who are at a similarly high cardiovascular (CV) risk. We hypothesized that 3D echocardiographic (3DE) measurements of EF and GLS, which are more reliable and reproducible, may have even better predictive value than the 2DE indices, and compared their ability to identify such patients. We retrospectively studied 104 inpatients with 2DE-derived LVEF of 30-50% who underwent transthoracic echocardiography during 2006-2010 period, had good quality images, and were followed-up through 2016. Both 2DE and 3DE images were analyzed to measure LVEF and GLS. Kaplan-Meier survival curves were generated for two subgroups defined by the median of each parameter as the cutoff. Of the 104 patients, 32 died of CV related causes. Cox regression revealed that 3D GLS was the only variable associated with CV mortality. Kaplan-Meier curves showed that 2D LVEF, 2D GLS and 3D EF were unable to differentiate patients at higher CV mortality risk, but 3D GLS was the only parameter to do so. Because 3D GLS is able to identify patients with mildly-to-moderately reduced LVEF who are at higher CV mortality risk, its incorporation into clinical decisions may improve survival of those who would benefit from therapeutic interventions not indicated according to the current guidelines.

Identifiants

pubmed: 30937684
doi: 10.1007/s10554-019-01589-7
pii: 10.1007/s10554-019-01589-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1573-1579

Références

Circulation. 1975 Sep;52(3):408-12
pubmed: 1157237
N Engl J Med. 2002 Mar 21;346(12):877-83
pubmed: 11907286
J Am Coll Cardiol. 2003 Aug 20;42(4):736-42
pubmed: 12932612
Circulation. 2005 Dec 13;112(24):3738-44
pubmed: 16330684
J Am Coll Cardiol. 2007 Sep 18;50(12):1150-7
pubmed: 17868806
N Engl J Med. 2009 Oct 1;361(14):1329-38
pubmed: 19723701
Am J Cardiol. 2009 Dec 15;104(12):1755-62
pubmed: 19962489
Circ Cardiovasc Imaging. 2010 May;3(3):249-56
pubmed: 20233858
Circulation. 2011 Mar 15;123(10):1061-72
pubmed: 21357819
J Am Coll Cardiol. 2012 May 15;59(20):1799-808
pubmed: 22575319
J Am Coll Cardiol. 2012 Nov 13;60(20):2074-81
pubmed: 23083779
J Am Coll Cardiol. 2013 Jan 22;61(3):e6-75
pubmed: 23265327
J Am Coll Cardiol. 2013 Jun 11;61(23):2365-73
pubmed: 23563128
Circulation. 2013 Oct 15;128(16):1810-52
pubmed: 23741057
J Am Soc Echocardiogr. 2014 Jan;27(1):65-73
pubmed: 24161481
J Am Soc Echocardiogr. 2014 May;27(5):493-500
pubmed: 24582162
N Engl J Med. 2014 May 1;370(18):1694-701
pubmed: 24678999
Heart. 2014 Nov;100(21):1673-80
pubmed: 24860005
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473
JACC Cardiovasc Imaging. 2015 Mar;8(3):235-45
pubmed: 25682511
PLoS One. 2015 May 15;10(5):e0127044
pubmed: 25978372
JACC Cardiovasc Imaging. 2015 Dec;8(12):1351-1359
pubmed: 26577264
J Am Soc Echocardiogr. 2016 Jun;29(6):522-527.e3
pubmed: 27068546
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
Circ Cardiovasc Imaging. 2017 Mar;10(3):
pubmed: 28264868
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
J Am Soc Echocardiogr. 2017 Apr;30(4):372-392
pubmed: 28385280
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
JACC Cardiovasc Imaging. 2018 Nov;11(11):1569-1579
pubmed: 29153577

Auteurs

Diego Medvedofsky (D)

Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.

Roberto M Lang (RM)

Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.

Lynn Weinert (L)

Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.

David M Tehrani (DM)

Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.

Akhil Narang (A)

Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA.

Victor Mor-Avi (V)

Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA. vmoravi@bsd.uchicago.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH